Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (DE:JNJ)
:JNJ
JNJ Stock Chart & Stats
€173.74
-€0.18(-0.13%)
At close: 4:00 PM EST
€173.74
-€0.18(-0.13%)
Day’s Range― - ―
52-Week Range€128.16 - €179.72
Previous CloseN/A
Volume223.00
Average Volume (3M)3.94K
Market Cap
€417.77B
Enterprise Value€463.68B
Total Cash (Recent Filing)€18.56B
Total Debt (Recent Filing)€6.39B
Price to Earnings (P/E)18.3
Beta0.19
Next Earnings
Jan 21, 2026EPS Estimate
2.17Last Dividend Ex-Date
Nov 25, 2025Dividend Yield2.55%
Share Statistics
EPS (TTM)2.40
Shares Outstanding2,409,295,200
10 Day Avg. Volume3,825
30 Day Avg. Volume3,942
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.83
Price to Sales (P/S)3.88
P/FCF Ratio17.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€179.87Price Target Upside3.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Orthopedic Business Spin-offThe spin-off of the Orthopaedics segment, expected to be tax-free, is anticipated to accelerate revenue and operating margins.
Revenue And Sales GrowthManagement has raised its 2025 reported sales forecast, indicating confidence in exceeding current consensus expectations for revenue and earnings per share.
Stock PerformanceJNJ shares have continued their impressive performance, with the stock up approximately 30% since July 1.
Bears Say
Deal StrategyJohnson & Johnson talks down doing any big deals – suggests smaller ones are more likely.
Tax Rate ExpectationsJNJ now expects a higher tax rate of 17.5%-18.0% due to the OBBBA.
Valuation ConcernsThe company's valuation is considered above-average, even when factoring in the higher multiple for the MedTech business, implying it is fairly valued.
Johnson & Johnson News
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was €128.16 and its highest was €179.72 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is €417.77B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jan 21, 2026 which is in 44 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Oct 14, 2025. The company reported €2.403 earnings per share for the quarter, beating the consensus estimate of €2.366 by €0.037.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of €1.124 which represents an annual dividend yield of 2.55%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.17.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,295,200 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of €2.403 in its last earnings report, beating expectations of €2.366. Following the earnings report the stock price went down -1.774%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in DE:JNJ
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€179.87 (3.53% Upside)
€179.87 (3.53% Upside)
Blogger Sentiment
Bullish
DE:JNJ Sentiment 70%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth $3.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.18%
12-Months-Change
Fundamentals
Return on Equity
33.62%
Trailing 12-Months
Asset Growth
8.15%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
JNJ Company Deck
JNJ Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Johnson & Johnson demonstrated strong overall performance with significant growth across key segments and successful new product launches. Despite challenges from STELARA's loss of exclusivity and increased tax rates, the company's strategic focus and operational achievements suggest a positive outlook.View all DE:JNJ earnings summariesJNJ Sales Breakdown
64.13% Innovative Medicine
35.87% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
€179.87
▲(3.53% Upside)
Technical Analysis
Options Prices
Currently, No data available
---